# A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

> **NCT00813995** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 395 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Comparator: Sitagliptin phosphate
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00813995
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-09
- **Primary completion:** 2010-08-09
- **Final completion:** 2010-08-09
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813995, "A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00813995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*